Keith Colburn
Rheumatology · Colton, CANPI 1477570869
Payments from drug & device makers
Across 673 payments — averaging $19.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Amgen$3K
- UCB, Inc.$1K
- GSK$1K
- Johnson & Johnson$572
- Pfizer$522
- plus $3K from 20 others
What the payments were for
- Food & beverage$12,72199%
- Education$1521%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 207 | $3,434 |
| Amgen(2 entities) | 148 | $2,939 |
| UCB, Inc. | 59 | $1,328 |
| GSK | 46 | $1,060 |
| Johnson & Johnson | 25 | $572 |
| Pfizer | 36 | $522 |
| Lilly USA, LLC | 37 | $463 |
| AstraZeneca(2 entities) | 25 | $463 |
| E.r. Squibb & Sons, L.L.C. | 18 | $345 |
| Novartis | 18 | $315 |
| Aurinia Pharma U.S., Inc. | 12 | $296 |
| Boehringer Ingelheim | 8 | $234 |
| Octapharma USA, Inc. | 3 | $124 |
| Radius Health, Inc. | 5 | $123 |
| Genentech USA, Inc. | 5 | $120 |
| ANI Pharmaceuticals, Inc. | 4 | $109 |
| Cumberland Pharmaceuticals, Inc. | 2 | $88 |
| Sandoz | 4 | $77 |
| Mallinckrodt Enterprises LLC | 2 | $58 |
| Sobi, Inc | 2 | $50 |
| Sanofi | 2 | $39 |
| Fresenius Kabi USA, LLC | 1 | $28 |
| Mallinckrodt Hospital Products Inc. | 1 | $27 |
| Organon | 1 | $21 |
| Bioventus LLC | 1 | $19 |
| Tonix Medicines, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,873 in reported general payments places this provider in the 70th percentile of 808 rheumatology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 103 | $830,646 |
| Humira(Cf) PenAdalimumab | 54 | $390,993 |
| Enbrel SureclickEtanercept | 17 | $121,163 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 11 | $112,806 |
| BenlystaBelimumab | 20 | $99,380 |
| EnbrelEtanercept | 13 | $96,066 |
| Orencia ClickjectAbatacept | 11 | $59,906 |
| Actemra ActpenTocilizumab | 23 | $54,171 |
| ProliaDenosumab | 12 | $19,588 |
| Hydroxychloroquine Sulfate | 219 | $11,917 |
| SavellaMilnacipran Hcl | 12 | $10,891 |
| Duloxetine Hcl | 200 | $6,756 |
| MethotrexateMethotrexate Sodium | 171 | $5,594 |
| Diclofenac Sodium | 81 | $5,288 |
| Cevimeline Hcl | 25 | $4,566 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Savella | $3,434 | $841,537115 claims |
| AmgenEnbrel, Prolia | $2,939 | $115,65525 claims |
| GSKBenlysta | $1,060 | $99,38020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 808 rheumatology providers in California.
Other rheumatology in Colton
- Samy MetyasCovina$12.9M
- Christine ThaiHuntington Beach$8.5M
- Tien-I SuWhittier$8.4M
- Eric LeeUpland$6.9M
- Orrin TroumSanta Monica$6.9M
- Shirley PangFullerton$5.7M
- William RobinsonStanford$5.1M
- Dan laTujunga$5.1M
- Christina Charles-SchoemanLos Angeles$4.8M
- Suneet GrewalWest Hollywood$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.